

MINUTES OF MEETING OF GRIEVANCE COMMITTEE TO ADDRESS THE GRIEVANCES RECEIVED IN BULK PURCHASE OF MEDICINES FOR THE YEAR 2024-25.

Dated: 08-06-2024

A meeting of Grievance Committee to address the Grievances received in Bulk Purchase of Medicines for the year 2024-25 was held on 08.06.24 in the office of Prof. Dr. Farah Shafi, Professor of Medicine, Chairman Grievance Committee Lahore General Hospital Lahore.

2. The Following members attended the meeting:

- | | |
|---|-------------|
| 1. Prof. Dr. Farah Shafi, Prof. of Medicine | Chairperson |
| 2. Prof. Dr. Khizer Hayat, Prof. of Urology | Member |
| 3. Prof. Dr. Faheem Afzal Prof. of Pediatrics | Member |
| 4. Dr. Ghias-ul-Hassan, Assistant Prof. of Gastroenterology | Member |
| 5. Mrs. Saadia Arshad Rana, DDC/Technical Officer LGH, Lahore | Member |
3. Following firms submitted grievances;

Sr.	Name of Firms
1	M/s Ameer & Adnan Pharmaceuticals Pvt Ltd
2	M/s GT Pharma Pvt. Ltd
3	M/s Linta Pharmaceuticals Pvt. Ltd.
4	M/s Next Pharmaceutical
5	M/s Brookes Pharma Pvt. Ltd.
6	M/s Ipram International
7	M/s Bajwa Pharmaceuticals Pvt. Ltd
8	M/s Bio-Labs Pvt. Ltd
9	M/s Hoover Pharmaceuticals Pvt. Ltd.
10	M/s Rotex Pharma Pvt. Ltd.
11	M/s Jassh Pharma
12	M/s Martin Dow Ltd.
13	M/s Allied distributors
14	M/s Muller & Phipps

The committee after briefed discussion and hearing the firm's representatives unanimously decided the grievances as under;

Dr. Farah Shafi


Sr. No	Grievance submitted by	TEC Result	Grievance Committee Decision
1	<p>M/s Ameer & Adnan Pharmaceuticals Pvt. Ltd. submitted grievance vide letter No.2535/LGH, Dated 29-05-2024, firm stated as under:</p> <p>"With due respect we M/S Ameer and Adnan pharmaceutical had applied for participation in tender quoted in LGH hospital for the year 2024. We have submitted all required documents. But technical evaluation team of your institution has declared us as non-responsive due to invalid cGMP certificate of our company.</p> <p>We want bring to your knowledge that we have applied in tender participation of Jinnah Hospital Lahore and Allied Hospital Faisalabad after expiration of our cGMP Certificate. They have issued us purchase order of our products. Purchase orders are attached with this application.</p> <p>Our renewal of cGMP is delayed by the respected DRAP. We have already applied for renew of our certificate with in due date. A reminder application for cGMP inspection has also written to DRAP. Application for renewal of cGMP certificate is attached here. The inspection is still pending from DRAP department."</p>	<p>All the products quoted by Ameer & Adnan Pharma were non responsive in TEC due to invalid cGMP.</p>	<p>Mr. Awais Aslam (QAM) attended the meeting on behalf of M/S Ameer & Adnan Pharmaceuticals Pvt. Ltd. The representative explained the matter in detail. The Grievance Redressal Committee evaluated the matter by checking the evaluation criteria in the bidding documents. As per clause 8 of evaluation criteria "valid" Good Manufacturing Certificate issued by DRAP is a compulsory parameter. While cGMP of manufacturing firm is expired so is not acceptable. Technical advice was also sought from legal adviser for final conclusion.</p> <p>After due deliberation and detailed discussion, the Committee unanimously decided to UPHOLD the decision of Technical Evaluation Committee (T.E.C).</p> <p>Hence the grievance is REJECTED</p>
2	<p>M/s GT Pharma Pvt. Ltd. submitted grievance vide letter No. 2539/LGH Dated 29-05-2024 against the responsiveness of their competitor's product Inj. Vit-K quoted by M/s English Pharma.</p> <p>Firm claims as under:</p> <p>We would like to bring to your attention some significant concerns regarding the efficacy of the product inj vitamin k quoted by English Pharma which is quoted against Sr no 165 in your bulk purchase of medicine for financial year 2024-2025.</p> <p>After the physical inspection of Director General Health Service Punjab the technical evaluation report issues great concern regarding the efficacy of the products. Following are the objections raised against English Pharma by DGHS Physical inspection.</p> <ol style="list-style-type: none"> 1. No validation studies of MS specifications were provided 2. Testing of pharmaceuticals was being performed on in-house methods but the label claim was USP specs. E.g. Escitalopram tablet and iron sucrose complex. 3. All the equipment including atomic absorption, TOC, Karl fisher, were calibrated by DAWN calibration laboratories recognized by PNAC. The log books of said equipment were 	<p>M/s English Pharma is technically responsive against T.E.# 165 in TEC Result</p>	<p>Mr. Yasir Ali (D. Manager) attended the meeting on behalf of M/S GT Pvt. Ltd. The representative explained their grievance against M/S English and presented an inspection report issued by Director General Health Services (DGHS). The Grievance Redressal Committee evaluated the matter. The Drug Regulatory Authority of Pakistan has renewed current Good Manufacturing Practice certificate to the said firm on 27.11.2023 with validity until 27.11.2026. Since DRAP is the regulatory authority of Pakistan for declaration and cancellation of registration of medicines and their manufacturing facilities.</p> <p>After due deliberation and detailed discussion, the Committee unanimously decided to UPHOLD the decision of T.E.C.</p> <p>Hence the grievance is REJECTED.</p>





- not in place they were asked to provide but they were not provided.
4. The DAWN Calibration lab is an accredited lab by the PNAC for seven parameters but they have calibrated all the equipment which are out of their scope.
 5. On inspection of chemicals, many of the chemicals were not having their opening date and expiry date, and few of the chemicals were found expired.
 6. No data of reagents standardization was available.
 7. The cleanliness of the lab was compromised.
 8. One of the two stability chamber was found under maintenance.

Keeping in view the above observations during physical inspection the mandatory parameter of the products are compromised leading in to sub-standard declaration of the product from DTLs of Punjab over 5% (report attached for ready reference).
This declaration of substandard products will lead into the delay of patient treatment and loss of public money as well

We understand the importance of providing patients with the best possible care, and ensuring the efficacy and safety of medications is a key. So we kindly request that you review the quality of vitamin k injection of English Pharma to ensure that it meets the necessary standards for patients treatment

We know that the prestigious institute like children hospital does not compromise on quality and efficacy of the products so kindly declare English Pharma as non-responsive.

M/s Linta Pharmaceutical Pvt. Ltd. submitted grievance vide letter No. 2540/LGH Dated 29-05-2024 against the TEC result.
M/s Linta Pharma stated as under:

•We Linta Pharmaceutical (Pvt) Limited are renowned pharmaceutical manufacturing company having good alliance with Govt. and semi-Government institute for the supply of our quality products at economical rates.
We have participated in LGH Tender for drugs and medicine for year 2024-25 and declared non responsive due to missing the below mentioned documents.

We are pleased to submit our the following documents against missing documents.

T.E. No.	Item Name	Missing Documents	Document
3			

TEC Results:
T.E.Nos. 189, Non-Responsive (GMP of API is missing- Product experience is missing)

T.E.No.251 Non-Responsive (Product experience is missing)

T.E.No. 306 Non-Responsive (GMP of API is expired)

Mr. Yasir (Institutional Manager) attended the meeting on behalf of M/S Linta Pharmaceuticals. The firm representative was asked to describe the grievance in detail. The committee scrutinized the matter through bidding documents, evaluation criteria and documents in the bid. It is concluded that some compulsory documents are missing in the bid or expired so are not considered valid. After due deliberation and detailed discussion, the Committee unanimously decided to **UPHOLD** the decision of Technical Evaluation Committee. Hence the grievance is **REJECTED**.

Yasir

Dr.

Yasir

			Attached/ Remarks
189	C-Terazim Tablets 10mg	GMP of API Product experience is missing	Attached all valid relevant documents
251	Hicon Tab 400mg	Product experience is missing	Attached
306	Ompalin 20mg Capsules	GMP of API is expired	Attached valid GMP of API

We are submitting all above documents as per your requirements and request you to declare a responsive bidder to ensure healthy competition between bidders in procurement of medicine."

M/s Next Pharmaceutical submitted grievance vide letter No. 2541/LGH Dated 29-05-2024 against the TEC result as non-responsive of their products;

Firm stated as under:

As the technical committee technically rejected our Products due to expire GMP, we would like to inform you that our GMP is expired on 17-02-2024 and we already have submitted the request for renewal of GMP to DRAP in December 2023 and the confirmation letter from DRAP regarding confirmation of request received on 15 march 2024 (documents attached for your reference) Moreover, we would like to inform you that our inspection for GMP has been conducted on 27-05-2024 and we will receive the renewed GMP shortly and we will submit the same also as it will have received to us.

Furthermore, on our item at Tender Sr no 170, 200, 207, 314 it is stated that GMP of API is expired. In this regard we would like to submit updated GMP of API for these items for your reference.

In the light of above said facts we would request you to kindly accept our Grievance and consider our products for healthy competition.

All quoted items of M/s Next Pharmaceutical against T.E Nos.170,200, 207,210,225,250, 278,279,284 & 314 are non-responsive in TEC result.

Mr. Tayyab (Institutional Manager) attended the meeting on behalf of M/S Next Pharmaceuticals. The firm representative was asked to describe the grievance in detail. The committee scrutinized the matter through bidding documents, evaluation criteria and documents in the bid. It is concluded that "Good Manufacturing Certificate" issued by the Drug Regulatory Authority of Pakistan is expired upon tender opening date (02.04.2024) so is considered not valid (Clause 8). Technical advice was also sought from legal advisers for final conclusion. After due deliberation and detailed discussion, the Committee unanimously decided to **UPHOLD** the decision of Technical Evaluation Committee. Hence the grievance is **REJECTED**.

4

[Signature]

[Signature]

[Signature]

M/s Brookes Pharma submitted grievance vide letter No. 2542/1 GH Dated 29-05-2024 against the responsiveness of their competitor M/s Kohinoor Industries in the Technical Evaluation Report for Item TE# 401 - 'Solution Povidone Iodine - 450ml' and Item TE# 403 - 'Scrub Povidone Iodine - 450ml'. **Firm claims are as under;**
 "However, recent developments have highlighted significant quality concerns. There is a proliferation of substandard products posing as Pyodine in the market. These low-quality products lack the efficacy and reliability of authentic Pyodine, resulting in numerous complaints nationwide. Such instances not only jeopardize the health and safety of patients but also risk the integrity of our esteemed institution due to increased infection risks.

M/s. Kohinoor Industries has limited production and marketing experience, as evidenced by their non-participation in DGHS Punjab's Prequalification for FY 2024-25. Their products lack substantial end-user acceptances and have been declared non-responsive by other reputable hospitals/institutes in Punjab for FY 2024-25. Furthermore, the actual shelf life of Kohinoor's products is only **two years**, which is substandard and indicates an inability to maintain efficacy throughout the intended period.

Conversely, Brookes Pharma is the largest manufacturer of the Pyodine range, supplying to top institutions such as DGHS Punjab, MCC KPK, MSD Balochistan, PIMS Hospital Islamabad, The Aga Khan Hospital, Shifa International Hospital Islamabad, and FG Poly Clinic Islamabad, among others. Pyodine's widespread acceptance and its ranking as No. 1 in the antiseptic class by IQVIA, with a 95% market share, are testaments to its unmatched quality.

We anticipate your kind consideration and a favorable response."

M/s Ipram International submitted grievance bearing diary No.2589/LGH, Dated 27-05-2024 with the reason **Ambiguity in Drug Registration Certificate in Item # 114 Inj. Meropenem Igm Clarification: firm stated as under;**

"This is to inform your kind honor that our product Inj. Meropenem Igm registered in October, 2007 with registration # 047724 which were mentioned in our technical bid. Afterward Drug Regulatory Authority issued instruction in 2016 for Separate carbapenem Section and we got grant of addition Section on 11 April 2017

M/s Kohinoor Industries is technically responsive in TEC Result

As per TEC result T.E.No. 114 was Non-Responsive due to ambiguity in DRC number of product

Mr. Shahid Hameed (business manager) attended the meeting on behalf of M/S Brookes Pharma. The representative explained the grievance regarding the quality of Solution & Scrub Povidone iodine of M/s Kohinoor industries. The committee evaluated the matter by checking experience of the said firm in multiple institutions.
 After due deliberation and detailed discussion, the Committee unanimously decided to **UPHOLD** the decision of Technical Evaluation Committee.
 Hence the grievance is **REJECTED**.

Mr. Khawar Iqbal (Institution Manager) attended the meeting on behalf of M/s Ipram International. The representative explained the matter in detail. The matter was evaluated by the committee and it is found that DRC of the product quoted by the firm is not cancelled by the DRAP. After due deliberation and detailed discussion, the Committee unanimously decided to declare item at T.E 114 as **RESPONSIVE**.
 Hence the grievance is **ACCEPTED**.

Dr. [Signature]
[Signature]
 6

<p>Letter attached and also got registration again on 26th September, 2017 of Inj. Meropenem 1 gm with same brand name with other carbapenem products. Furthermore it is stated that our registration in Inj. Meropenem are 2nd to brand leader and we are using our 1st registration for Inj. Meropenem due to technical experience since 2007.</p> <p>Registration letter with all renewal submitted in DRAP are attached herewith.</p> <p>Hopefully above mentioned clarification are suffice for your kind honor for declaration of our product Meropenem item # 114) as Responsive.</p> <p>Therefore you are hereby requested to provide us the opportunity to serve the patients of your prestigious institute as well. "</p> <p>Furthermore, if you require any additional information or assistance, we are available in any way.</p>		
<p>M/s Bajwa Pharmaceuticals Pvt. Ltd. submitted grievance bearing diary No. 5159/LGH. Dated 25-05-2024 against the rejection of their product T.E.No.36 Inj. At racurium Besylyate by the end user.</p> <p>Firm is stating that:</p> <p>"Our products are leading in Anesthesia Group and we are supplying in government hospitals as well as in private sectors but we don't have such complaints of clinical efficacy. Documents have also been provided in the Technical bid.</p> <p>Our APIs are FDA/WHO approved as data provided in bidding documents. We are quality conscious and CGMP Certified company. Dear sir your honorable Institute made verdict on the behalf of few samples given with bidding documents. Kindly give us opportunity to provide you trail samples in bulk with proper cold chain</p> <p>Because our products are cost-effective with approved APIs. This economy will help you to buy some more medicine for patient welfare and we request you to please consider us in your grievance meeting for which we shall remain your thankful with very kind regards."</p>	<p>TEC Result: T.E.No. 36 quoted by Bajwa Pharmaceuticals Non-Responsive (Rejected by end-users, not satisfactory as per Therapeutic efficacy)</p>	<p>Mr. Sultan Mehmood (Zonal Sales Manager) attended the meeting on behalf of M/s Bajwa Pharmaceuticals. The representative explained the matter in detail about the quality of their product. The matter was evaluated and advice was also sought from concerning department Head. The product was rejected by the end user.</p> <p>After due deliberation and detailed discussion, the Committee unanimously decided to UPHOLD the decision of Technical Evaluation Committee (T.E.C.). Hence the grievance is REJECTED.</p>
<p>M/s Bio-Labs submitted its grievance bearing diary No.5199/LGH. Dated 25-05-2024 against the technically non responsive item at T.E.No.155 Inj. Tigacycline 50mg. Firm's statement is as under:</p> <p>"sir we import its API from M/s Funan Pharmaceuticals Group china and currently Health Department of China not issuing fresh GMP certificate according to previous format. Now they are issuing certificate of a Pharmaceutical product which confirms to the</p>	<p>TEC Result: T.E.No. 155, Non Responsive due to GMP of API invalid.</p>	<p>Mr. Adnan Riaz (Sales Manager) attended the meeting on behalf of M/s Bio Labs. The representative explained the matter in detail. The Grievance Redressal Committee scrutinized the relative documents and found these valid. After due deliberation and detailed discussion, the Committee unanimously decided to declare item at T.E 155 as RESPONSIVE.</p>

format recommended by the WHO (copy attached). Firm provided this certificate but even then, the committee rejected the said document.

Firm is requesting to accept their grievance and amend the evaluation report for a Healthy competition for Inj. Tigecycline 50mg.

Hence grievance is **ACCEPTED**.

M/s Hoover Pharmaceuticals Pvt. Ltd. submitted grievance vide letter No.5235LGH. Dated 27-05-2024. Firm submitted that their products are technically non responsive due to:

- GMP certificate of the firm (we have already applied for the GMP certificate renewal letter and challan is attached.
- API source of quoted items (valid sources of API are attached

All the quoted products of Hoover Pharmaceuticals are non-responsive due to lack of documents i.e. cGMP of firm is expired-- GMP of API is expired

Mr. Imran Ahmad (Sales Representative) attended the meeting on behalf of M/S Hoover Pharmaceuticals to describe the grievance matter. The committee scrutinized the matter by checking various documents in question like cGMP. It is concluded that some compulsory documents are expired so are not considered valid. Technical advice regarding cGMP of firm was also sought from legal adviser for final conclusion.

After due deliberation and detailed discussion, the Committee unanimously decided to **UPHOLD** the decision of Technical Evaluation Committee (T.E.C.). Hence the grievance is **REJECTED**.

10 M/s Rotex Pharma submitted grievance bearing diary No. 5218/LGH. Dated 29-05-2024 and stated that their firm was non responsive due to expired GMP of firm.
Firm is stating that they are submitting fresh / valid GMP for ready reference with the hope they will be marked as responsive.

T.E Nos. 116,117,288,289 & 305 quoted by Rotex Pharma are non-responsive due to invalid cGMP

Mr. Tayyab (Institutional Manager) attended the meeting on behalf of M/S Rotex Pharma. The firm representative was asked to describe the grievance in detail. The committee scrutinized the matter through bidding documents, evaluation criteria and documents in the bid.

It is concluded that "Good Manufacturing Certificate" issued by the Drug Regulatory Authority of Pakistan was expired upon tender opening date (02.04.2024) so is considered not valid (Clause 8). Technical advice was also sought from legal adviser for final conclusion.
After due deliberation and detailed discussion, the Committee unanimously decided to **UPHOLD** the decision of Technical Evaluation Committee. Hence the grievance is **REJECTED**.

[Handwritten signatures and initials]

<p>11</p> <p>M/s Jassh Pharma submitted grievance bearing diary No.5147 dated 25-05-2024 against its competitor's product. Firm is claiming that one batch of quoted item of 3N LifeMed got declared "spurious/ adulterated" from DTL on dated 23 Nov, 2021, and the firm was blacklisted in Children Hospital Lahore.</p>	<p>M/s 3N Lifemed quoted single item T.E. No:406 (Hemodialysis Concentrate Solution) and responsive in TEC.</p>	<p>Mr. Salman (Sales Manager) attended the meeting on behalf of M/S Jassh Pharma. The firm representative explained the grievance against M/S 3N Lifemed in detail. The committee scrutinized the matter through bidding documents, evaluation criteria and affidavits attached in the bid of said firm. It is revealed that bulk supply of the said firm was declared Spurious in Children Hospital Lahore and so was black listed due to that reason. Moreover the affidavit regarding Non declaration of Spurious batch by DTL was submitted by the firm M/S 3 N Lifemed as per clause 10(ii) of evaluation criteria.</p>
<p>12</p> <p>M/s Martin Dow submitted grievance bearing diary No.5157. Dated 25-05-2024 against its competitor M/s Global Pharma's products against T.E # 103, 136 and 137. firm stated as under: "We, Martin Dow Limited, a renowned pharmaceutical manufacturing company having good alliance with Govt. and semi-Government institute for the supply of our quality products at economical rates. We would like to bring to your attention some significant concerns regarding the efficacy of the products quoted by Global Pharma in your bulk purchase of medicine for financial year 2024-2025. After the inspection of Director General Health Service Punjab the technical evaluation report shows that the cGMP of Global Pharma is expired due to which the products are compromised leading in to Sub-standard declaration of the products which in results affects the patient health. We understand the importance of providing patients with the best possible care, and ensuring the efficacy and safety of medications is a key. So we kindly request you to review the cGMP to ensure that it meets the necessary standards for patients treatment. We know that the prestigious institute like Lahore General Hospital does not compromise on quality and efficacy of the products so kindly declare Global Pharma as non-responsive. Looking forward for your positive response."</p>	<p>All the quoted products of Global Pharma are responsive in TEC.</p>	<p>After due deliberation and detailed discussion, the Committee unanimously decided to declare the bid of <u>M/S 3 N Lifemed</u> as Non Responsive. Hence the grievance M/s Jassh Pharma is ACCEPTED. Mr. Zaheer Abbas (Institutional Sales Manager) attended the meeting on behalf of M/S Martin Dow. The firm representative explained the grievance against M/S Global in detail. The committee scrutinized the matter through bidding documents, evaluation criteria and documents in the bid. It is concluded that "cGMP Certificate" issued by the Drug Regulatory Authority of Pakistan was expired upon tender opening date (02.04.2024) so is considered not valid (Clause 8). Technical advice was also sought from legal adviser for final conclusion. After due deliberation and detailed discussion, the Committee unanimously decided to declare all the items/ bid of <u>M/S Global Pharma</u> as Non Responsive. Hence the grievance of M/s Martin Dow is ACCEPTED.</p>

[Handwritten signatures]

M/s Allied Distributors submitted grievance bearing diary No.5547, Dated 25.05.24 against the rejection of their item at T.E. No.140 Inj. Propofol.

Firm stated as under:

"Reference subject matter it has been noted that a discriminatory approach has been adopted by your esteemed institution to keep our product Pofol (Propofol 200mg 20ml) out of competition.

In tender specification to keep POFOL out, they make it happen by writing that we need "Inj. Propofol MCT/LCT".

Why they do this we don't know although it is very well known to everyone that may it be Inj. Propofol MCT/LCT or Inj. Propofol LCT there is no difference. Both are Propofol giving the same results.

Before going in detail we would like to inform that our Pofol is an imported product & the said product is imported from Dong Kook Pharmaceutical, Seoul - Korea. Dong Kook is following EU guidelines of EDQM (European Directorate for the Quality of Medicine). Further, Dong Kook has successfully synthesized Propofol & developed a Propofol-based emulsion for use in injections. The company has patents pending for its manufacturing techniques covering both the Propofol (material) and the emulsion. Patents for Propofol (material) manufacturing techniques are pending in 19 countries.

DongKook is gaining fame as a global pharmaceutical maker in over 50 countries worldwide. Countries covered by global networks:

Europe: 10 countries including Germany, England, Italy, Spain, and Austria Middle East: 10 countries including Turkey, Iran, Syria, Egypt and JordanAsia: 15 countries including Japan, China, India, Pakistan, Vietnam, Thailand and Indonesia Central South America: 15 countries including Brazil, Mexico, Peru, Columbia, and Chile Now Coming to efficacy, claiming that Propofol MCT/LCT does not cause pain is baseless, it is only a gimmicked approach spread by the firm promoting Inj. Propofol MCT/LCT. We can prove it by providing not only international but national studies that the claim of not causing pain is baseless. Pain on injection: A double-blind comparison of propofol with lidocaine pretreatmentversus propofol formulated with long and medium-chain triglycerides. This study was done by Schaub E, Kern C, Landau R published in Service d'Anesthesiologie, Switzerland The

In TEC Result T.E 140 inj. Propofol quoted by said firm is non-responsive (out of specification)

No one attended the meeting on behalf of M/S Allied Distributors. However the matter was discussed by the committee to conclude it. It is found that quoted product of the aggrieved firm does not conform the advertised specifications of the product at T.E 140. Moreover items are advertised with specifications provided by the end users. After due deliberation and detailed discussion, the Committee unanimously decided to UPHOLD the decision of Technical Evaluation Committee. Hence the grievance is **REJECTED**.

Handwritten signatures and initials at the top of the page.

<p>conclusion of the study was: In contrast to previous reports, we found that propofol -LCT/MCT resulted in a more frequent incidence of pain than propofol 1% with IV lidocaine pretreatment. Another study done in Department of Anesthesiology, Institute of Kidney Diseases and Lady Reading Hospital Peshawar - Pakistan</p> <p>Objective of this study was, "To determine if propofol-MCT/LCT premixed with lignocaine as well as given alone is effective in reducing pain on injection". Conclusion: Propofol MCT/LCT alone does not provide any advantage to reduce pain on injection in comparison to propofol MCT/LCT premixed with lignocaine. (Complete study is enclosed) In the above mentioned studies now it is clearly mentioned that both products cause same intensity of pain and to reduce the pain you have to use lidocaine may it propofol MCT/LCT or propofol LCT. So it can be concluded that there is no advantage of propofol MCT/LCT over propofol LCT with reference to reduction in pain. That is why we initially mention in our letter that it is a total gimmickry & the well reputed institutions should not fall in this trap & purchase an expensive product. Another most important point is that when you are imposing some condition on any product as</p> <p>in case of Pofol by writing MCT/LCT it means you are creating monopoly whereas, according to Competition Commission of Pakistan (CCP). The Competition Commission of Pakistan (CCP) is an independent quasi-regulatory, quasi-judicial body that helps ensures healthy competition between companies for the benefit of the economy. The Commission prohibits abuse of a dominant position in the market, certain types of anti-competitive agreements, and deceptive market practices.</p> <p>So firm is requesting to consider the product as responsive.</p>		
<p>M/s Muller & Phipps submitted grievance bearing diary No. 59524 Dated 26.05.24</p> <p>Firm stated as under:</p> <p>"Presentus Kabi manufactured Propofol 1% MCT Presentus and Propofol 1% MCT/LCT Presentus under these brand names and other names. 1 ml of Propofol 1% MCT/LCT contains 10 mg Propofol (active ingredient)</p> <p>Propofol MCT/LCT is a formulation of Propofol emulsion with similar pharmacokinetics and efficacy as standard Propofol, but reduces the amount of free Propofol in the emulsion thereby causing less pain on injection site than Propofol.</p>	<p>14</p>	<p>Mr. Tariq Shahid (Senior Regional Sales Manager) accompanied with Mr. Farooq (Senior Institutional Sales Officer) attended the meeting on behalf of M/s Muller and Phipps. The representatives of the firm described their grievance and explained technical points regarding Propofol injection with MCT/LCT and MCT.</p> <p>The committee referred the case to the Head of Department of Anesthesia (End User) to comment over scientific/technical aspects. The said department submitted its report (copy attached). In the report he maintained that said product does not conform the advertised specifications as given</p>

Propofol is one of the safest drugs in the induction of general anesthesia. The routinely available preparation in market being Propofol LCT (long chain triglycerides) which do have a disadvantage of pain on injection site. This pain is very discomforting for the patient and also anesthesiologist. So, FK introduced a new preparation Propofol MCT (medium chain triglycerides - Long chain triglycerides) which do have a property of reduction of pain on injection site.

We import and sale product under the name of "Propofol 1% MCT Fresenius Emulsion for Injection or Injiston" (Propofol 10mg) Diprivan is the brand name of Propofol Inj, which is registered in the USA by FK. Whereas FK Germany manufactured same product formulation in Europe under the name of Propofol 1% MCT Fresenius and other similar names (see attached registration status). Also for your kind information & record that we have won the same Tender "Inj. Propofol MCT/Fresenius" for FY 2022-23 as per your demand of Propofol MCT/LCT & we have supplying this same product in your hospital for approx. one year. We kindly request that you recognize our products and declare as RESPONSIVE."

Literature presented by the company was not related to the one registered in Pakistan so can not be considered. The Grievance Redressal Committee endorsed the said recommendations. After due deliberation and detailed discussion, the Committee unanimously decided to UPHOLD the decision of Technical Evaluation Committee. Hence the grievance is **REJECTED**.

Meeting ended with the vote of thanks to the chair;

Mrs. Snadia Arshad Rana
DDC/ Technical Officer LGH, Lahore

Dr. Ghias-ul-Hassan,
Assistant Prof. of Gastroenterology

Prof. Dr. Faheem Afzal
Prof. of Pediatrics

Prof. Dr. Khizer Hayat,
Prof. of Urology

Prof. Dr. Farah Shafi,
Prof. of Medicine